USRE34878E - Hypoglycemic agent - Google Patents

Hypoglycemic agent Download PDF

Info

Publication number
USRE34878E
USRE34878E US08/157,564 US15756493A USRE34878E US RE34878 E USRE34878 E US RE34878E US 15756493 A US15756493 A US 15756493A US RE34878 E USRE34878 E US RE34878E
Authority
US
United States
Prior art keywords
phenylalanine
derivative
substituted
trans
methanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime, expires
Application number
US08/157,564
Inventor
Shigeshi Toyoshima
Yoshiko Seto
Hisashi Shinkai
Koji Toi
Izumi Kamashiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Priority to US08/157,564 priority Critical patent/USRE34878E/en
Application granted granted Critical
Publication of USRE34878E publication Critical patent/USRE34878E/en
Adjusted expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Definitions

  • the present invention relates to hypoglycemic agents useful as antidiabetic drugs.
  • a D-phenylalanine derivative represented by the general formula: ##STR3## or a salt thereof, or a precursor which can be converted thereto in the human or animal body Such compounds can lower the value of blood sugar and thus can be used as an antidiabetic drug for an oral use as well as by injection.
  • R 1 is hydrogen, alkyl of 1 to 5 carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, and sec-butyl, aryl of 6 to 12 carbon atoms such as phenyl, tolyl, naphthyl, and ##STR5## aralkyl of 6 to 12 atoms such as benzyl, ##STR6## --CH 2 CO 2 R 3 , --CH(CH 3 )--OCO--R 3 , or --CH 2 --OCO--C(CH 3 ) 3 , R 2 is a group comprising aryl of 6 to 12 carbon atoms such as phenyl, naphthyl, and indanyl, a hetero six-membered ring such as quinolynyl, pyridyl, a hetero five-membered ring such as 2-benzofuranyl, cycloalkyl such as
  • substituents include a halogen atom such as fluorine or chlorine, a hydroxyl group, a C 1-5 alkyl group such as methyl, ethyl, trichloromethyl, trifluoromethyl, propyl, isopropyl, n-butyl, sec-butyl, and tert-butyl, a C 1-5 alkenyl group such as ethenyl, propenyl, and butenyl, an alkylidene group such as ##STR7## a C 1-5 alkyloxy such as methoxy and ethoxy, a C 1-5 alkyl group which has been substituted by such C 1-5 alkyloxy group such as methoxymethyl and 1-ethoxyethyl, a C 1-5 alkylene group which has been substituted by such C 1-5 alkyloxy group in the same manner as above such as 1-methoxyethylene.
  • a halogen atom such as fluorine or chlorine
  • R 1 stands for a hydrogen atom
  • it can be formed by conventional methods via the salts thereof with various cations such as an alkali metal, for example sodium and potassium, an alkali earth metal, for example, calcium, an inorganic base, for example, ammonia, an organic base, for example, cyclohexylamine, N-methyl-D-glucosamine, or a basic amino acid (lysine, arginine and the like).
  • the D-phenylalanine derivative as shown by the formula (I) mentioned above can be prepared by using conventional N-acylating reactions as in the Examples given below.
  • the D-phenylalanine derivatives used in the present invention are useful as a hypoglycemic agent for treating diabetic mammals including humans.
  • the derivatives can be used for lowering blood sugar by formulating them into a preparation such as tablets, capsules, and elixirs for oral administration and into an aseptic liquid preparation or an aseptic suspension preparation for parenteral administration such as subcutaneous, intramuscular, intavenous injection, and suppositories.
  • the D-phenylalamine derivatives in the present invention can be administered to a subject necessitating such treatment (animals and humans) in a dosage range of 0.1 to 1,000 mg per subject generally several times a day, that is, in a total daily dosage of 0.2 to 2,000 mg.
  • the dosages varies according to the seriousness of disease, the body weight of subjects, and other factors acknowledged by those skilled in the art.
  • D-phenylalanine derivatives as described above for the present invention, they may be converted to dosage forms such as tablets, granules, powders, capsules, injections and suppositories by conventional methods.
  • the D-phenylalanine derivative as the principal agent, adjuvants such as fillers, binders, disintegrators, lubricants, colors, and correctives, as necessary, and then formed by conventional methods into tablets, coated tablets, granules, powders, capsules and the like.
  • Examples of specific materials which can be incorporated into tablets, capsules, and so forth are as follows: fillers such as cornstarch, lactose, white sugar, glucose, sorbitol, and crystalline cellulose; binders such as polyvinyl alcohol, polyvinyl ether, ethyl cellulose, methyl cellulose, gum arabic, tragacanth gelatine, shellac, hydroxypropyl cellulose, hydroxypropyl starch, polyvinyl pyrrolidone; disintegrators such as starch, agar, gelatine powder, crystalline cellulose, calcium carbonate, sodium bicarbonate, calcium citrate, dextrin and pectin; lubricants such as magnesium stearate, talc, polyethylene glycol, silica, hardened plant oil; colors such as one which is allowed as an additive for the medicines; correctives such as cocoa powder, mentha herb, aromatic acid, mentha oil, borneol, cinnamon bark powder.
  • binders such as poly
  • the injectable formulations there may be added to the phenylalanine derivative as the principal agent, a pH adjusting agent, a buffer agent, a stabilizing agent, preservatives or the like, as necessary to produce a material for subcutaneous, intramuscular or intravenous injection by conventional methods.
  • D-Phenylalaine 2 g (12 mmole) was dissolved in 10% aqueous sodium hydroxide solution (10 ml), and acetone (10 ml) was added.
  • An acetone (5 ml) solution of 4-ethyl benzoyl chloride (2.5 g, 15 mmole) and a 10% aqueous sodium hydroxide solution were added dropwise to the mixture obtained above while stirring and cooling with ice over 20 minutes, the reaction solution being maintained at pH 10.
  • the reaction solution was returned to the room temperature, stirred for 3 hours, and made an acidic with a dilute hydrochloric acid solution to precipitate crystals.
  • the crystals were filtered, washed with water and recrystallized from ethyl acetate to obtain N-(4-ethylbenzoyl)-D-phenylalanine (3.0 g, yield 83%).
  • Cyclopentane carboxylic acid (1.5 g, 13 mmole) was dissolved in chloroform (50 ml), and N-hydroxysuccinimide 1.7 g was added.
  • N,N'-Dicyclohexylcarbodiimide (3.0 g) was gradually added to the mixture as obtained above while stirring and cooling with ice, and the mixture was stirred for 1 hour at the same temperature. The mixture was further stirred for 7 hours at room temperature. Glacial acetic acid (2 ml) was added to the mixture, and stirred for 1 hour. The insoluble matter was removed by filtration.
  • N-(4-isopropylcyclohexylcarbonyl)-D-phenylalanine was produced. It was crystallized from methanol-water to give the desired product (2.5 g, yield 61%).
  • ICR-CDI mice (Male, five weeks old, Body weight: 20 g) which had been bred for one week, were abstained from food for 18 hours, and then used as test subjects.
  • the phenylalanine derivative of the present invention was suspended in 0.5% CMC-0.05M tris-hydrochloride buffer (pH 7.4).
  • the sample solution thus obtained was administered orally in fixed amounts to the test subjects. A predetermined time later, the percentage decrease in blood glucose with the comparison to the control group was determined. The results are shown in the following table.
  • the filtrate was washed with saturated aqueous sodium bicarbonate (300 ml) and water (300 ml), and dried over magnesium sulfate.
  • the magnesium sulfate was removed by filtration, and the filtrate thus obtained was concentrated under reduced pressure to dryness.
  • the resultant substance was recrystallized from ethyl acetate to obtain cumic acid N-hydroxysuccinimide ester (18.8 g, yield 72 mmole).
  • the ester thus obtained above (18.8 g) was added to the chloroform solution (150 ml) of D-phenylalanine methyl ester hydrochloride (23.0 l g, 110 mmole) and triethylamine (10.8 g, 110 mmole), and the mixture thus obtained was stirred for 15 hours at room temperature.
  • the reaction solution was washed with 1N aqueous hydrochloric acid solution (300 ml), saturated aqueous sodium bicarbonate (300 ml) and water (300ml) and dried over magnesium sulfate.
  • the magnesium sulfate thus used was removed by filtration, and the filtrate thus obtained was concentrated under reduced pressure to dryness.
  • the methyl ester (9.0 g) thus obtained was dissolved in methanol (50 ml), and 1N aqueous sodium hydroxide solution (50 ml) was added thereto.
  • the mixture thus obtained was stirred for 10 minutes at room temperature and made acidic with an addition of a dilute aqueous hydrochloric acid solution to precipitate crystals.
  • the crystals were filtered, washed with water, and crystallized from methanol-water to give trans-4-isopropylcyclohexane carboxylic acid (6.8 g, yield 78%).
  • ICR-CDI mice (Male, five weeks old, Body weight: 20 g) were abstained from food for 18 hours, and then used as test subjects.
  • the phenylalanine derivative of the present invention was suspended in 0.5% CMC-0.14M sodium chloride buffer solution (pH 7.4).
  • the solution thus obtained was administered orally in fixed volume amounts to the test subjects. After a predetermined time, the percentage decrease of the blood glucose against the control group was determined. The results are shown in the following Table.
  • D-phenylalanine derivatives as described above can be used as an antidiabetic drug for oral administration as well as the more usual parenteral administration.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A compound of D-phenylalanine derivative for hypoglycemic use, represented by the general formula ##STR1## R1 is selected from hydrogen, alkyl of 1 to 5 carbon atoms, aryl of 6 to 12 carbon atoms, aralkyl of 6 to 12 carbon atoms, ##STR2## --CH2 CO2 R3, --CH(CH3)--OCO--R3, and --CH2 --OCO--C(CH3)3 ; R2 is selected from groups comprising aryl of 6 to 12 carbon atoms, a hetero six-membered ring, a hetero five-membered ring, cycloalkyl, or cycloalkenyl, any of which groups may have one or more substituents; and R3 is selected from hydrogen and alkyl of 1 to 5 carbon atoms; the salts thereof, and precursors which can be converted thereto in the human or animal body.
Some of the compounds are novel per se.

Description

This application .Iadd.is a Reissue of Ser. No. 07/146,719, filed Feb. 21, 1988, U.S. Pat. No. 4,816,182, which is a .Iaddend.divisional of Ser. No. 844,970, filed Mar. 27, 1986, now abandoned.
FIELD OF THE INVENTION
The present invention relates to hypoglycemic agents useful as antidiabetic drugs.
BACKGROUND TO THE INVENTION
Hitherto, as antidiabetic drugs for oral use, there have been widely employed sulfonyl urea which shows hypoglycemic action particularly through a promotion of the secretion of insulin, and a biguanide which shows a hypoglycemic action particularly through the metabolism of sugar. However, they are somewhat unsatisfactory as to their side effects (see Textbook of Endocrinology 4th ed., 1968, p. 719 (Saunders); Diabetes, 19, 785, 1970; Ann. Rev. Pharmacol., 15, 351, 1975).
No report has ben found that a D-phenylalanine derivative possesses hypoglycemic action.
SUMMARY OF THE INVENTION AND DESCRIPTION OF PREFERRED EMBODIMENTS
According to one aspect of the invention there is provided for pharmaceutical, particularly hypoglycemic, use, a D-phenylalanine derivative represented by the general formula: ##STR3## or a salt thereof, or a precursor which can be converted thereto in the human or animal body. Such compounds can lower the value of blood sugar and thus can be used as an antidiabetic drug for an oral use as well as by injection.
Among the foregoing phenylalanine derivatives, those in the D-form represented by the general formula: ##STR4## and the salts thereof are novel.
In the above general formulae: R1 is hydrogen, alkyl of 1 to 5 carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, and sec-butyl, aryl of 6 to 12 carbon atoms such as phenyl, tolyl, naphthyl, and ##STR5## aralkyl of 6 to 12 atoms such as benzyl, ##STR6## --CH2 CO2 R3, --CH(CH3)--OCO--R3, or --CH2 --OCO--C(CH3)3, R2 is a group comprising aryl of 6 to 12 carbon atoms such as phenyl, naphthyl, and indanyl, a hetero six-membered ring such as quinolynyl, pyridyl, a hetero five-membered ring such as 2-benzofuranyl, cycloalkyl such as cyclohexyl and cyclopentyl, bicycloalkyl such as bicycloheptye, and cycloalkenyl such as 1-cyclohexenyl, 2-cyclohexeneyl, 3-cyclohexenyl, 1-cyclopentenyl and 2-cyclopentenyl, any of which groups optionally having one or more substituents; R3 is hydrogen or lower alkyl such as methyl, ethyl, isopropyl and pentyl; and R4 stands for those R2 groups which provide novel compounds hereof, notably phenyl which has one or more alkyl substituents of 2 to 5 carbon atoms, cyclohexyl which has one or more substituents cyclopentyl, bicycloalkyl, cycloalkenyl, indanyl or 2-benzofuranyl, any of which may have one or more substituents.
When an organic group in the above general formulae has a substituent, examples of such substituents include a halogen atom such as fluorine or chlorine, a hydroxyl group, a C1-5 alkyl group such as methyl, ethyl, trichloromethyl, trifluoromethyl, propyl, isopropyl, n-butyl, sec-butyl, and tert-butyl, a C1-5 alkenyl group such as ethenyl, propenyl, and butenyl, an alkylidene group such as ##STR7## a C1-5 alkyloxy such as methoxy and ethoxy, a C1-5 alkyl group which has been substituted by such C1-5 alkyloxy group such as methoxymethyl and 1-ethoxyethyl, a C1-5 alkylene group which has been substituted by such C1-5 alkyloxy group in the same manner as above such as 1-methoxyethylene. In the case of a substituted bicycloalkyl group as stated above, it can include a bicycloheptyl or a derivative thereof such as bicyclo (2,2,1)heptyl.
In the case of the compound represented by the general formula (I) wherein R1 stands for a hydrogen atom, it can be formed by conventional methods via the salts thereof with various cations such as an alkali metal, for example sodium and potassium, an alkali earth metal, for example, calcium, an inorganic base, for example, ammonia, an organic base, for example, cyclohexylamine, N-methyl-D-glucosamine, or a basic amino acid (lysine, arginine and the like).
The D-phenylalanine derivative as shown by the formula (I) mentioned above, can be prepared by using conventional N-acylating reactions as in the Examples given below.
Most of the phenylalanine derivatives supplied by this invention are novel compounds which have not been described yet in the literature.
The D-phenylalanine derivatives used in the present invention are useful as a hypoglycemic agent for treating diabetic mammals including humans. The derivatives can be used for lowering blood sugar by formulating them into a preparation such as tablets, capsules, and elixirs for oral administration and into an aseptic liquid preparation or an aseptic suspension preparation for parenteral administration such as subcutaneous, intramuscular, intavenous injection, and suppositories. The D-phenylalamine derivatives in the present invention can be administered to a subject necessitating such treatment (animals and humans) in a dosage range of 0.1 to 1,000 mg per subject generally several times a day, that is, in a total daily dosage of 0.2 to 2,000 mg. The dosages varies according to the seriousness of disease, the body weight of subjects, and other factors acknowledged by those skilled in the art.
To produce the preparations using the D-phenylalanine derivatives as described above for the present invention, they may be converted to dosage forms such as tablets, granules, powders, capsules, injections and suppositories by conventional methods.
For the production of oral preparations, there may be added the to the D-phenylalanine derivative as the principal agent, adjuvants such as fillers, binders, disintegrators, lubricants, colors, and correctives, as necessary, and then formed by conventional methods into tablets, coated tablets, granules, powders, capsules and the like.
Examples of specific materials which can be incorporated into tablets, capsules, and so forth are as follows: fillers such as cornstarch, lactose, white sugar, glucose, sorbitol, and crystalline cellulose; binders such as polyvinyl alcohol, polyvinyl ether, ethyl cellulose, methyl cellulose, gum arabic, tragacanth gelatine, shellac, hydroxypropyl cellulose, hydroxypropyl starch, polyvinyl pyrrolidone; disintegrators such as starch, agar, gelatine powder, crystalline cellulose, calcium carbonate, sodium bicarbonate, calcium citrate, dextrin and pectin; lubricants such as magnesium stearate, talc, polyethylene glycol, silica, hardened plant oil; colors such as one which is allowed as an additive for the medicines; correctives such as cocoa powder, mentha herb, aromatic acid, mentha oil, borneol, cinnamon bark powder. These tables and granules may be coated with sugar, gelatine, or the like, as desired.
For the production of the injectable formulations, there may be added to the phenylalanine derivative as the principal agent, a pH adjusting agent, a buffer agent, a stabilizing agent, preservatives or the like, as necessary to produce a material for subcutaneous, intramuscular or intravenous injection by conventional methods.
EXAMPLES
The present invention will be further explained in the following examples.
EXAMPLE 1 N-(4-Ethylbenzoyl)-D-phenylalanine
D-Phenylalaine 2 g (12 mmole) was dissolved in 10% aqueous sodium hydroxide solution (10 ml), and acetone (10 ml) was added. An acetone (5 ml) solution of 4-ethyl benzoyl chloride (2.5 g, 15 mmole) and a 10% aqueous sodium hydroxide solution were added dropwise to the mixture obtained above while stirring and cooling with ice over 20 minutes, the reaction solution being maintained at pH 10. The reaction solution was returned to the room temperature, stirred for 3 hours, and made an acidic with a dilute hydrochloric acid solution to precipitate crystals. The crystals were filtered, washed with water and recrystallized from ethyl acetate to obtain N-(4-ethylbenzoyl)-D-phenylalanine (3.0 g, yield 83%).
m.p. 165.5°-166° C. Specific Rotation [α]D 23 +4.4° (C=1, methanol).
EXAMPLES 2 TO 11
For Examples 2 to 8, in the same manner as in Example 1, using the following starting materials, each compound of 50 mmole, the following product compounds were produced. The compounds in Examples 9 to 11 were already known, and therefore were produced in accordance with the following literature references:
Example 9: J. Amer. Chem. Soc., 73, 1644, 1951,
Example 10: Pol. J. Chem., 53, 2239, 1979, and
Example 11: J. Chromatogr., 264, 63, 1983.
__________________________________________________________________________
Example                                                                   
     Starting          Yield                                              
                           M.P.  Specific                                 
No.  Material Product  (%) (°C.)                                   
                                 Rotation                                 
__________________________________________________________________________
2    D-phenylalanine                                                      
              N-(4-toldryl)-                                              
                       83  152-155                                        
                                 [α].sub.D .sup.28 +46.2°    
              D-phenylalanine    (C = 0.5, methanol)                      
3    D-phenylalanine                                                      
              N-(2-fluoro-                                                
                       74  91.5-93.5                                      
                                 [α].sub.D .sup.19 -8.8°     
              benzoyl)-D-        (C = 1, methanol)                        
              phenylalanine                                               
4    D-phenylalanine                                                      
              N-(3-fluoro-                                                
                       81  112.5-116                                      
                                 [α].sub.D .sup.22 +48.6°    
              benzoyl)-D-        (C = 1, methanol)                        
              phenylalanine                                               
5    D-phenylalanine                                                      
              N-(4-fluoro-                                                
                       80  142-145                                        
                                 [α].sub.D .sup.28 +40.4°    
              benzoyl)-D-        (C = 0.5, methanol)                      
              phenylalanine                                               
6    D-phenylalanine                                                      
              N-(3-trifluoro-                                             
                       77  118-119                                        
                                 [α].sub.D .sup.28 +40.4°    
              methylbenzoyl)-    (C + 1, methanol)                        
              D-phenylalanine                                             
7    D-phenylalanine                                                      
              N-(4-trifluoro-                                             
                       70    136-137.5                                    
                                 [α].sub.D .sup.28 +36.3°    
              methylbenzoyl)-    (C = 1, methanol)                        
              D-phenylalanine                                             
8    D-phenylalanine                                                      
              N-4-anisoyl)-D-                                             
                       65  85-90 [α].sub.D .sup.20 +60.2°    
              phenylalanine      (C = 0.5, methanol)                      
9    D-phenylalanine                                                      
              N-benzoyl-D-                                                
                       81                                                 
              phenylalanine                                               
10   D-phenylalanine                                                      
              N-nicotinoyl-                                               
                       62                                                 
              D-phenylalanine                                             
11   D-phenylalanine                                                      
              N-(2-naphthoyl)-                                            
                       83                                                 
              D-phenylalanine                                             
__________________________________________________________________________
EXAMPLE 12 N-Cyclopentylcarbonyl-D-phenylalanine
Cyclopentane carboxylic acid (1.5 g, 13 mmole) was dissolved in chloroform (50 ml), and N-hydroxysuccinimide 1.7 g was added. N,N'-Dicyclohexylcarbodiimide (3.0 g) was gradually added to the mixture as obtained above while stirring and cooling with ice, and the mixture was stirred for 1 hour at the same temperature. The mixture was further stirred for 7 hours at room temperature. Glacial acetic acid (2 ml) was added to the mixture, and stirred for 1 hour. The insoluble matter was removed by filtration. The filtrate was washed with saturated aqueous sodium bicarbonate solution (30 ml), 1N aqueous hydrochloric acid solution (30 ml), and water (30 ml), and dried over magnesium sulfate. The magnesium sulfate was removed by filtration, and the solution thus obtained was concentrated under reduced pressure to dryness. The matter was recrystallized from ethyl acetate to afford cyclopentane carboxylic acid N-hydroxysuccinimide ester (2.5 g, yield 91%).
The ester derivative thus obtained above (2.5 g), was dissolved in chloroform (20 ml). This solution was added to a chloroform solution (40 ml) of D-phenylalanine methyl ester hydrochloride (3.0 g, 14 mmole) and triethylamine (1.4 g), and the mixture thus obtained was stirred for 18 hours at room temperature. The reaction solution was washed with 1N aqueous hydrochloric acid solution (40 ml), saturated aqueous sodium bicarbonate solution (40 ml) and water (40 ml), and dried over magnesium sulfate. The magnesium sulfate was removed by filtration and the filtrate was concentrated under reduced pressure to dryness. The matter was recrystallized from ethyl acetate-n-hexane to afford N-cyclopentylcarbonyl-D-phenylalanine methyl ester (3.0 g, yield 84%).
The methyl ester derivative (3.0 g) thus obtained above, was dissolved in methanol (10 ml), and 1N aqueous sodium hydroxide solution (20 ml) was added. The mixture was stirred for 30 minutes at room temperature and then made acidic with an addition of a dilute hydrochloric acid to precipitate crystals. The crystals were filtered, washed with water, and recrystallized from methanol-water to give the desired product (2.7 g, yield 80%).
m.p. 108°-110° C. Specific Rotation [α]D 22 -35.2° (C=0.5, methanol).
EXAMPLES 13 TO 18
For Examples 13 to 16, in the same manner as in Example 12, using as the starting material the following compounds, each of 15 mmole, the following products were obtained. The compounds of Examples 17 and 18 stated in the above table were known, and therefore were produced in accordance with the following literature references:
Example 17: BEXXA BELG. NO. 893553, 48, 1981, and
Example 18: Bull. Chem. Soc. Jpn., 57, 2171, 1984.
__________________________________________________________________________
Example                                                                   
     Starting          Yield                                              
                           M.P. Specific Rotation                         
No.  Material                                                             
             Product   (%) (°C.)                                   
                                [α].sub.D .sup.22 (C = 0.5,         
__________________________________________________________________________
                                methanol                                  
13   2-benzofurane                                                        
             N-(2-benzofuran-                                             
                       59  114-116                                        
                                +89.6°                             
     carboxylic                                                           
             yl-carbonyl)-                                                
     acid    D-phenylalanine                                              
14   5-indane                                                             
             N-(5-indanyl-                                                
                       64  160-161                                        
                                +52.0°                             
     carboxylic                                                           
             carbonyl)-                                                   
     acid    D-phenylalanine                                              
15   3-cyclohexene                                                        
             N-(3-cyclo-                                                  
                       62  100-101                                        
                                -12.6°                             
     carboxylic                                                           
             hexenylcarbonyl-)                                            
     acid    D-phenylalanine                                              
16   bicyclo-                                                             
             N-(bicyclo-                                                  
                       50  179-181                                        
                                +33.4°                             
     [2,2,1]heptan-                                                       
             [2,2,1]heptan-2-                                             
     2-ylcarboxylic                                                       
             ylcarbonyl)-D-                                               
     acid    phenylalanine                                                
17   cyclohexene                                                          
             N-cyclohexyl-                                                
                       65                                                 
     carboxylic                                                           
             carbonyl-D-                                                  
     acid    phenylalanine                                                
18   benzoic acid                                                         
             N-benzoyl-D-                                                 
                       65                                                 
             phenylalanine                                                
             methyl ester                                                 
__________________________________________________________________________
EXAMPLE 19 N-(4-Isopropylcyclohexylcarbonyl)-D-phenylalanine
Platinum oxide (200 mg) as a catalyst was suspended in acetic acid (20 ml), and then (s)-(-)perillic acid (2 g, 12 mmole) was added. The mixture thus obtained was stirred for 8 hours at room temperature under a current of hydrogen gas. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure to a dryness. The matter was recrystallized from methanol-water to obtain 4-isopropyl cyclohexane carboxylic acid (1.9 g, yield 93%).
After that, in the same manner as the reaction in Example 1, N-(4-isopropylcyclohexylcarbonyl)-D-phenylalanine was produced. It was crystallized from methanol-water to give the desired product (2.5 g, yield 61%).
m.p. 230°-232° C. Specific Rotation [α]D 22 -28.2° (C=0.5, methanol).
EXAMPLE 20
ICR-CDI mice (Male, five weeks old, Body weight: 20 g) which had been bred for one week, were abstained from food for 18 hours, and then used as test subjects.
The phenylalanine derivative of the present invention was suspended in 0.5% CMC-0.05M tris-hydrochloride buffer (pH 7.4). The sample solution thus obtained was administered orally in fixed amounts to the test subjects. A predetermined time later, the percentage decrease in blood glucose with the comparison to the control group was determined. The results are shown in the following table.
______________________________________                                    
Decrease in Blood Glucose (%)                                             
Example No. Amounts used (mg/kg)                                          
                            60 Minutes                                    
______________________________________                                    
1            25             34                                            
2           100             32                                            
3           100             24                                            
4           100             24                                            
5           100             43                                            
6           250             37                                            
7           100             33                                            
8           100             38                                            
9           100             34                                            
10          250             19                                            
11          250             17                                            
12           50             22                                            
13          100             31                                            
14          250             28                                            
15          100             28                                            
16          250             16                                            
17          100             27                                            
18          250             37                                            
19           25             50                                            
______________________________________
EXAMPLE 21 N-Cumoyl-D-Phenylalanine
Cumic acid (15.0 g, 91 mmole) was dissolved in chloroform (150 ml), and N-hydroxysuccinimide (11.4 g, 99 mmole) was added thereto. N,N'-Dicyclohexylcarbodiimide (20.4 g, 99 mmole) was added gradually to the mixture obtained above while cooling with ice and stirring, and then the mixture thus obtained was returned to room temperature. The mixture was further stirred for 15 hours at room temperature. Glacial acetic acid (5 ml) was added thereto, and the mixture thus obtained was stirred and the insoluble matter was removed by filtration. The filtrate was washed with saturated aqueous sodium bicarbonate (300 ml) and water (300 ml), and dried over magnesium sulfate. The magnesium sulfate was removed by filtration, and the filtrate thus obtained was concentrated under reduced pressure to dryness. The resultant substance was recrystallized from ethyl acetate to obtain cumic acid N-hydroxysuccinimide ester (18.8 g, yield 72 mmole).
The ester thus obtained above (18.8 g) was added to the chloroform solution (150 ml) of D-phenylalanine methyl ester hydrochloride (23.0 l g, 110 mmole) and triethylamine (10.8 g, 110 mmole), and the mixture thus obtained was stirred for 15 hours at room temperature. The reaction solution was washed with 1N aqueous hydrochloric acid solution (300 ml), saturated aqueous sodium bicarbonate (300 ml) and water (300ml) and dried over magnesium sulfate. The magnesium sulfate thus used was removed by filtration, and the filtrate thus obtained was concentrated under reduced pressure to dryness.
The residue thus obtained was recrystallized from ethyl acetate-n-hexane to obtain N-cumoyl-D-phenylalanine methyl ester (20.5 g, yield 69%).
The methyl ester thus obtained above (20.5 g) was dissolved in methanol (100 ml), and then 1N aqueous sodium hydroxide (100 ml) was added thereto. The mixture thus obtained was stirred for 10 minutes at room temperature, and was made acidic with an addition of diluted aqueous hydrochloric acid solution to precipitate crystals. The crystals were filtered, washed with water and recrystallized from methanol-water to give the desired product (18.1 g, yield 64%).
m.p. 177°-178° C. Specific Rotation [α]D 20 +25.5° (C=1, methanol).
EXAMPLES 22 to 30
In the same manner as in Example 21, using as the starting material the following compounds, each at 50 mmole, the following product compounds were produced.
__________________________________________________________________________
Example                                                                   
     Starting         Yield                                               
                          M.P.  Specific                                  
No.  Material                                                             
            Product   (%) (°C.)                                    
                                Rotation                                  
__________________________________________________________________________
                                [α].sub.D .sup.20 (C = 1,           
                                methanol)                                 
22   (s)-perillic                                                         
            N-[(s)-   44  109-110                                         
                                -37.2°                             
     acid   perilloyl]-D-                                                 
            phenylalinine                                                 
23   trans-4-n-                                                           
            N-(trans-4-n-                                                 
                      48  104-105                                         
                                -8.8°                              
     propylcyclo-                                                         
            propylcyclo-                                                  
     hexane hexylcarbonyl)-                                               
     carboxylic                                                           
            D-phenylalanine                                               
     acid                                                                 
24   trans-4-n-                                                           
            N-(trans-4-n-                                                 
                      50  144-145                                         
                                -7.5°                              
     butylcyclo-                                                          
            butylcyclohexyl-                                              
     hexane carbonyl)-D-                                                  
     carboxylic                                                           
            phenylalanine                                                 
     acid                                                                 
25   4-tert-butyl-                                                        
            N-(4-t-butyl-                                                 
                      55  177-178                                         
                                +51.5°                             
     benzoic acid                                                         
            benzoyl)-D-                                                   
            phenylalanine                                                 
26   cuminic acid                                                         
            N-cumoyl-L-                                                   
                      63  121-123                                         
                                [α].sub.D .sup.23 -29.3° (C  
                                = 1, methanol)                            
            phenylalanine                                                 
27   cyclopentane                                                         
            N-cyclopentyl-                                                
                      40  115-117                                         
                                [α].sub.D .sup.23 -30.1° (C  
                                = 1, methanol)                            
     carboxylic                                                           
            carbonyl-L-                                                   
     acid   phenylalanine                                                 
28   trans-4-                                                             
            N-(trans-4-                                                   
                      43  124-125                                         
                                [α].sub.D .sup.23 -11.5° (C  
                                = 1, methanol)                            
     methyl-cyclo-                                                        
            methylcyclohexyl-                                             
     hexane carbo-                                                        
            carbonyl)-D-phenyl-                                           
     xylic acid                                                           
            alanine                                                       
29   trans-4-ethyl-                                                       
            N-(trans-4-ethyl-                                             
                      53  96-97 [α].sub.D .sup.23 -11.1° (C  
                                = 1, methanol)                            
     cyclohexane                                                          
            cyclohexyl-carbo-                                             
     carboxylic                                                           
            nyl)-D-phenylala-                                             
     acid   nine                                                          
30   trans-4-t-                                                           
            N-(trans-4-t-                                                 
                      49  160-161                                         
                                [α].sub.D .sup.23 -9.0° (C = 
                                1, methanol)                              
     butyl-cyclo-                                                         
            butylcyclohexyl-                                              
     hexane carbo-                                                        
            carbonyl)-D-phenyl-                                           
     xylic acid                                                           
            alanine                                                       
__________________________________________________________________________
EXAMPLE 31 N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine
Platinum oxide (500 mg) as a catalyst was suspended in acetic acid (50 ml) and cumic acid (10 g, 61 mmole) was added thereto. The mixture thus obtained was stirred vigorously for 2 hours at room temperature under a pressure of hydrogen 5 kg/cm2. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure to a solid state. The resultant substance was distilled under reduced pressure of 1 mmHg (1.3×10-3 kg/cm2), at 113°-116° C. to obtain 4-isopropylcyclohexane carboxylic acid yielding 10 g (96%) in a ratio of 3 parts of cis-form per 1 part of trans-form by weight.
To methanol (70 ml) at less than -20° C., thionyl chloride (17 ml) was added dropwise, and the carboxylic acid (10 g) as obtained above was added. The mixture thus obtained was stirred for 15 hours at room temperature, and then concentrated under reduced pressure to a solid substance. The substance thus obtained was distilled under reduced pressure of 0.7 mmHg (9.2×10-4 kg/cm2) at 66° C. to obtain 4-isopropylcyclohexane carboxylic acid methyl ester (9.5 g, yield 88%).
To the methyl ester (b 9.5 g) thus obtained, sodium hydride (120 mg) was added, and the mixture was heated at 150° C. for 2 hours under a current of nitrogen gas. The reaction solution was cooled and then subjected to a reduced pressure distillation of 0.7 mmHG (9.2×10-4 kg/cm2) at 66° C. to obtain 4-isopropylcyclohexane carboxylic acid methyl ester in a ratio of 6 parts trans-form per 1 part cis-form.
The methyl ester (9.0 g) thus obtained was dissolved in methanol (50 ml), and 1N aqueous sodium hydroxide solution (50 ml) was added thereto. The mixture thus obtained was stirred for 10 minutes at room temperature and made acidic with an addition of a dilute aqueous hydrochloric acid solution to precipitate crystals. The crystals were filtered, washed with water, and crystallized from methanol-water to give trans-4-isopropylcyclohexane carboxylic acid (6.8 g, yield 78%).
After that, in the same manner as in Example 21, using as a starting material the carboxylic acid derivative (6.8 g, 40 mmole), N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine was produced, and recrystallized from methanol-water to give the desired product (8.2 g, yield 65%).
m.p. 129°-130° C. Specific Rotation [α]D 20 -9.4° (C=1, methanol).
EXAMPLES 32 TO 35
In the same manner as in Example 26, using as the starting material the following compounds, each of 40 mmole, the following product compounds were produced.
__________________________________________________________________________
Example                                                                   
     Starting         Yield                                               
                          M.P.   Specific Rotation                        
No.  Material                                                             
            Product   (%) (°C.)                                    
                                 [α].sub.D .sup.20 (C = 1,          
__________________________________________________________________________
                                 methanol)                                
32   trans-4-                                                             
            4-(trans-4-                                                   
                      52  137-138                                         
                                 +8.8°                             
     isopropyl-                                                           
            isopropylcyclo-                                               
     cyclohexane                                                          
            hexylcarbonyl)-D-                                             
     carboxylic                                                           
            phenylalanine                                                 
     acid   methyl ester                                                  
33   trans-4-                                                             
            N-(trans-4-                                                   
                      56  130-131                                         
                                 +9.5°                             
     isopropyl-                                                           
            isopropylcyclo-                                               
     cyolohexane                                                          
            hexylcarbonyl)-                                               
     carboxylic                                                           
            L-phenylalanine                                               
     acid                                                                 
34   trans-4-                                                             
            N-(trans-4-                                                   
                      66  134--135                                        
                                 --                                       
     isopropyl-                                                           
            isopropylcyclo-                                               
     cyclohexane                                                          
            hexylcarbonyl)-                                               
     carboxylic                                                           
            2-phenylethylamine                                            
     acid                                                                 
35   trans-4-                                                             
            N-(trans-4-                                                   
                      58    129--130.5                                    
                                 +8.4°                             
     isopropyl-                                                           
            isopropylcyclo-                                               
     cyclohexane                                                          
            hexylcarbonyl)-                                               
     carboxylic                                                           
            D-phenylalanine                                               
     acid   benzylester                                                   
__________________________________________________________________________
EXAMPLE 26 N-(Cis-4-isopropylcyclohexylcarbonyl)-D-phenylalanine
4-Isopropylcyclohexane carboxylic acid methyl ester (9.5 g) (Cis-form:trans-form=3:1) was obtained in the same manner as in Example 26. Cis-4-isopropylcyclohexane carboxylic acid methyl ester (7 g) was obtained from the product thus obtained by a high performance liquid chromatography of YMC A-043 column using as the solvent a mixture of n-hexane and 1,2-dichloro ethane in a ratio of 75:25.
After that, in the same manner as in Example 21, using as a starting material the cis-form thus obtained (6.5 g, 38 mmole), N-(Cis-4-isopropylcyclohexylcarbonyl)-D-phenylalanine was produced, and recrystallized from methanol-water to give the desired product (8 g, yield 66%).
m.p. 111°-112° C. Specific Rotation [α]D 20 -13.2° (C=1, methanol).
EXAMPLE 37
ICR-CDI mice (Male, five weeks old, Body weight: 20 g) were abstained from food for 18 hours, and then used as test subjects.
The phenylalanine derivative of the present invention was suspended in 0.5% CMC-0.14M sodium chloride buffer solution (pH 7.4). The solution thus obtained was administered orally in fixed volume amounts to the test subjects. After a predetermined time, the percentage decrease of the blood glucose against the control group was determined. The results are shown in the following Table.
______________________________________                                    
Example                                                                   
       Amounts used in sample                                             
                        Decrease in blood glucose                         
No.    mg/kg body weight                                                  
                        after 60 minutes (%)                              
______________________________________                                    
21     25               26                                                
22     100              43                                                
23     100              35                                                
24     100              30                                                
25     100              32                                                
26     100               0                                                
27     100               0                                                
28     6.25             24                                                
29     6.25             31                                                
30     6.25             30                                                
31     1.5              30                                                
32     6.25             37                                                
33     100              23                                                
34     100              14                                                
35     25               24                                                
36     100              27                                                
______________________________________
It is clear from the foregoing that the D-phenylalanine derivatives as described above can be used as an antidiabetic drug for oral administration as well as the more usual parenteral administration.

Claims (15)

We claim:
1. A D-phenylalanine derivative of the formula
R.sup.4 --CO--NR.sup.3 --CH(COOR.sup.1)--CH.sub.2 --C.sub.6 H.sub.5
or a salt thereof or a precursor which can be converted into said D-phenylalanine derivative in vivo, wherein:
R1 is hydrogen or C1-5 alkyl,
R.sup. is hydrogen or C1-5 alkyl; and
R4 is cyclohexane substituted at the 4- or 5-position by methyl, ethyl, ispropyl, tert-butyl, ethene, or isopropene or cyclohexene substituted at the 4- or 5-position by methyl, ethyl, isopropyl, tert-butyl, ethene, or isopropene.
2. The D-phenylalanine derivative of claim 1, wherein R4 is said substituted cyclohexane.
3. The D-phenylalanine derivative of claim 1, wherein R4 is said substituted cyclohexane.
4. The D-phenylalanine derivative of claim 1, wherein the said derivative is N-(4-isopropylcyclohexylcarbonyl)-D-phenylalanine.
5. The D-phenylalanine derivative of claim 1, wherein the said derivative is N-(4-isopropylcyclohexylcarbonyl)-D-phenylalanine: N-[(S)-perilloyl]-D-phenylalanine; N-(4-methylcyclohexylcarbonyl)-D-phenylalanine; N-(4-ethylcyclohexylcarbonyl)-D-phenylalanine; or N-(4-t-butylcyclohexylcarbonyl)-D-phenylalanine.
6. The D-phenylalanine derivative of claim 1, wherein the said derivative is N-[(s)-perilloyl]-D-phenylalanine; N-(trans-4-methylcyclohexylcarbonyl)-D-phenylalanine; N-(trans-4-ethylcyclohexylcarbonyl)-D-phenylalanine; N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine; or N-(trans-4-t-butylcyclohexylcarbonyl)-D-phenylalanine.
7. The D-phenylalanine derivative of claim 1, wherein R1 is hydrogen and R3 is hydrogen.
8. The D-phenylalanine derivative of claim 1, wherein R4 is perilloyl.
9. The D-phenylalanine derivative of claim 1, wherein said substituted cyclohexane is substituted at the 4-position.
10. The D-phenylalanine derivative of claim 1, wherein said substituted cyclohexane is substituted at the 5-position.
11. The D-phenylalanine derivative of claim 1, wherein said substituted cyclohexene is substituted at the 4-position.
12. The D-phenylalanine derivative of claim 1, wherein said substituted cyclohexene is substituted at the 5-position.
13. The D-phenylalanine derivative of claim 1, wherein said substituted cyclohexane or said substituted cyclohexene is substituted with methyl, ethyl, isopropyl or tert-butyl.
14. The D-phenylalanine derivative of claim 1, wherein said substituted cyclohexane or said substituted cyclohexene is substituted by ethene, or isopropene.
15. A pharmaceutical composition, comprising a D-phenylalanine derivative of claim 1 and a pharmaceutical excipient. .Iadd.16. The compound N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine. .Iaddend.
US08/157,564 1985-03-27 1993-11-23 Hypoglycemic agent Expired - Lifetime USRE34878E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/157,564 USRE34878E (en) 1985-03-27 1993-11-23 Hypoglycemic agent

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP6227685 1985-03-27
JP60-62276 1985-03-27
US84497086A 1986-03-27 1986-03-27
US07/146,719 US4816484A (en) 1985-03-27 1988-01-21 Hypoglycemic agent
US08/157,564 USRE34878E (en) 1985-03-27 1993-11-23 Hypoglycemic agent

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US07/146,719 Reissue US4816484A (en) 1985-03-27 1988-01-21 Hypoglycemic agent
US07844970 Division 1989-03-27

Publications (1)

Publication Number Publication Date
USRE34878E true USRE34878E (en) 1995-03-14

Family

ID=13195452

Family Applications (2)

Application Number Title Priority Date Filing Date
US07/146,719 Ceased US4816484A (en) 1985-03-27 1988-01-21 Hypoglycemic agent
US08/157,564 Expired - Lifetime USRE34878E (en) 1985-03-27 1993-11-23 Hypoglycemic agent

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US07/146,719 Ceased US4816484A (en) 1985-03-27 1988-01-21 Hypoglycemic agent

Country Status (4)

Country Link
US (2) US4816484A (en)
EP (1) EP0196222B1 (en)
JP (1) JPS6354321A (en)
DE (2) DE10199054I2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US20040116526A1 (en) * 2002-07-18 2004-06-17 Ronit Yahalomi Polymorphic forms of nateglinide
US20040152782A1 (en) * 2002-07-03 2004-08-05 Ronit Yahalomi Process for preparing nateglinide and intermediates thereof
US20040181089A1 (en) * 2002-07-18 2004-09-16 Ronit Yahalomi Polymorphic forms of nateglinide
US20050014949A1 (en) * 2002-07-18 2005-01-20 Ronit Yahalomi Polymorphic forms of nateglinide
US20050014836A1 (en) * 2002-07-18 2005-01-20 Gustavo Frenkel Crystalline form of nateglinide
US20050075400A1 (en) * 2002-07-18 2005-04-07 Ronit Yahalomi Polymorphic forms of nateglinide
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US20050096367A1 (en) * 2002-05-28 2005-05-05 Yoshiro Kitahara Pharmaceutical composition for suppression of the expression of ATP citrate lyase and use thereof
US7615649B2 (en) 2006-01-26 2009-11-10 Iowa State University Research Foundation, Inc, Synthesis of polycyclic procyanidins
WO2011157986A1 (en) 2010-06-14 2011-12-22 Cipla Limited A process for the preparation of nateglinide
US10006830B2 (en) 2015-05-20 2018-06-26 Nexion S.P.A. Balancing machine

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2501432Y2 (en) * 1990-01-23 1996-06-19 ヤンマー農機株式会社 Seedling interval detection device in transplanter
FR2676056B1 (en) * 1991-05-03 1993-07-16 Adir NOVEL BENZOPYRAN DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
DE10199058I2 (en) * 1991-07-30 2006-04-27 Alcm Co Crystals of N- (trans-4-isopropylcyclohexylcarbonyl) -D-phenylalanine and process for their preparation
US5466864A (en) * 1993-02-25 1995-11-14 Ajinomoto Co., Inc. Method for recovering L-phenylalanine
US5831118A (en) * 1996-06-18 1998-11-03 Katayama Seiyakusyo Co., Ltd. Epimerization of 2- or 4- substituted cyclohexanecarboxylic acids
PT965339E (en) * 1996-11-15 2006-06-30 Ajinomoto Kk COMPOSITION OF NATEGLINIDE IN TABLETS
US20040176457A1 (en) * 2003-02-27 2004-09-09 Hemmingsen Lisbeth Tofte Novel NIDDM regimen
AU8163398A (en) 1997-06-23 1999-01-04 Pharmacia & Upjohn Company Inhibitors of alpha4beta1mediated cell adhesion
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
AR028299A1 (en) * 1999-09-17 2003-05-07 Novartis Ag A PHARMACEUTICAL COMPOSITION THAT INCLUDES NATEGLINIDA, A PROCESS FOR ITS PREPARATION AND THE USE OF SUCH COMPOSITION FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETY.
AU2005200818B2 (en) * 1999-09-17 2008-07-17 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
ATE346613T1 (en) 2000-01-21 2006-12-15 Novartis Pharma Gmbh COMPOSITIONS CONSISTING OF DIPEPTIDYLPEPTIDASE-IV INHIBITORS AND ANTIDIABETICS
SK14922002A3 (en) * 2000-03-17 2003-04-01 Ajinomoto Co., Inc. Drugs for complications of diabetes and neuropathy and utilization thereof
PE20020617A1 (en) 2000-08-22 2002-08-05 Novartis Ag COMPOSITION INCLUDING AN AT1 RECEPTOR ANTAGONIST AND AN INSULIN SECRETION POTENTIAL OR AN INSULIN SENSITIZER
DK1334963T3 (en) * 2000-10-18 2007-09-24 Ajinomoto Kk Process for the preparation of nateglinide crystal
AU2001294264A1 (en) * 2000-10-18 2002-04-29 Ajinomoto Co., Inc. Process for the preparation of acylphenylalanines
PT1334721E (en) * 2000-10-24 2009-06-01 Ajinomoto Kk Nateglinide-containing hydrophilic drug preparations
DK1334964T3 (en) * 2000-10-24 2007-09-24 Ajinomoto Kk Process for the preparation of B-form nateglinide crystals
US6740776B2 (en) 2001-07-16 2004-05-25 Novartis Ag Air oxidation of an aromatic aldehyde to an aromatic acid
CN1335182A (en) * 2001-08-08 2002-02-13 华中科技大学 Insulin spray for oral cavity and its prepn process
US20050101638A1 (en) * 2002-11-08 2005-05-12 Webb Randy L. Combination of organic compounds
EP1483232A1 (en) * 2002-03-11 2004-12-08 Novartis AG Salts of nateglinide
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
BR0309210A (en) * 2002-04-15 2005-02-09 Novartis Ag N- (trans-4-isopropyl cyclohexylcarbonyl) -d-phenylalanine crystal forms
JP4538842B2 (en) * 2002-04-15 2010-09-08 味の素株式会社 New nateglinide crystals
CN100363332C (en) * 2002-04-26 2008-01-23 中国人民解放军军事医学科学院毒物药物研究所 Aromatic amino acid derivative and its prepn process and medicinal use
KR20040111490A (en) 2002-04-29 2004-12-31 바이오콘 리미티드 Novel form of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine
AU2003241823A1 (en) * 2002-05-28 2003-12-12 Ajinomoto Co., Inc. Medicinal composition for inhibiting the expression of atp-citrate lyase and use thereof
CN100384813C (en) * 2002-07-03 2008-04-30 特瓦制药工业有限公司 Process for preparing nateglinide and intermediates thereof
AU2003253971A1 (en) * 2002-07-18 2004-02-09 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
JP2006513250A (en) * 2003-01-28 2006-04-20 中国科学院上海薬物研究所 Alanine compound, production method and use thereof
WO2004074330A1 (en) * 2003-02-18 2004-09-02 Konishi Co., Ltd. Curing resin, method for producing same and curing resin composition
HU227073B1 (en) * 2003-07-10 2010-06-28 Richter Gedeon Nyrt Process for the preparation of chirally pure n-(trans-4-isopropyl-cyclohexylcarbonyl)-d-phenyl-alanine (nateglinide) and it's crystalline forms and the cristalline form g
US7589233B2 (en) * 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US8173840B2 (en) * 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
JP2007505059A (en) * 2003-09-11 2007-03-08 ゾルファイ フルーオル ゲゼルシャフト ミット ベシュレンクテル ハフツング Production of N-acyl compounds
WO2005027981A1 (en) 2003-09-17 2005-03-31 Board Of Regents, The University Of Texas System Mechanism-based targeted pancreatic beta cell imaging and therapy
EP1656339A1 (en) * 2004-05-07 2006-05-17 Teva Pharmaceutical Industries Ltd Polymorphic forms of nateglinide
GB0413084D0 (en) * 2004-06-11 2004-07-14 Cipla Ltd Process
US7425648B2 (en) 2005-01-03 2008-09-16 A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. Process for the preparation of nateglinide, preferably in B-form
KR20070102694A (en) * 2005-01-31 2007-10-19 아지노모토 가부시키가이샤 Medicinal composition for ameliorating or treating glucose intolerance, borderline diabetes, insulin resistance and hyperinsulinemia containing hypoglycemic agent
GT200600381A (en) 2005-08-25 2007-03-28 ORGANIC COMPOUNDS
MY159522A (en) 2005-09-14 2017-01-13 Takeda Pharmaceuticals Co Administration of dipeptidyl peptidase inhibitors
AU2006311601A1 (en) * 2005-11-07 2007-05-18 Elixir Pharmaceuticals, Inc. Combinations of metformin and meglitinide
KR101399916B1 (en) * 2006-03-31 2014-05-28 아지노모토 가부시키가이샤 Process for production of carboxylic acid chloride compound
WO2007113650A2 (en) * 2006-04-05 2007-10-11 Cadila Pharmaceuticals Limited A novel and improved process fro the preparation of nateglinide and its polymorph form-h
CN100383114C (en) * 2006-07-21 2008-04-23 杭州保灵有限公司 Nateglinide preparing process
WO2009137082A1 (en) * 2008-05-08 2009-11-12 Concert Pharmaceuticals, Inc. 4-isopropylcyclohexylcarbonyl amino acid derivatives
SI2429995T1 (en) 2009-05-15 2014-05-30 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
EP2435402B1 (en) 2009-05-28 2016-04-13 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
NZ596304A (en) 2009-05-28 2014-01-31 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
EP2993169B1 (en) 2009-11-17 2017-12-20 Novartis AG Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
US8575160B2 (en) 2009-11-30 2013-11-05 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
US8802695B2 (en) 2010-02-03 2014-08-12 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
WO2012095548A2 (en) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compounds for treating neurodegenerative disorders
WO2013066277A1 (en) 2011-11-03 2013-05-10 Mahmut Bilgic Synergic compositions
WO2013077819A1 (en) 2011-11-23 2013-05-30 Mahmut Bilgic Pharmaceutical formulations comprising nateglinide
UY35144A (en) 2012-11-20 2014-06-30 Novartis Ag APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT
LT2956464T (en) 2013-02-14 2018-07-10 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
KR20160031551A (en) 2013-07-25 2016-03-22 노파르티스 아게 Cyclic polypeptides for the treatment of heart failure
MX2016001021A (en) 2013-07-25 2016-08-03 Novartis Ag Bioconjugates of synthetic apelin polypeptides.
SG11201704758XA (en) 2015-01-23 2017-08-30 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
JP6720512B2 (en) * 2015-11-27 2020-07-08 住友化学株式会社 Method for producing trans-cyclohexanecarboxylic acid
WO2017134212A1 (en) 2016-02-05 2017-08-10 Siegfried Ag Process for the preparation of trans-4-amino-1-cyclohexanecarboxilic acid and its derivatives
UY38072A (en) 2018-02-07 2019-10-01 Novartis Ag COMPOSITIONS DERIVED FROM BUTANOIC ESTER SUBSTITUTED WITH BISPHENYL AS INHIBITORS OF NEP, COMPOSITIONS AND COMBINATIONS OF THE SAME

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2102412A (en) * 1981-06-19 1983-02-02 Chugai Pharmaceutical Co Ltd Proline derivatives and process for producing the same
EP0093551A2 (en) * 1982-04-30 1983-11-09 Ajinomoto Co., Inc. Pharmaceutical composition
US4650785A (en) * 1982-04-30 1987-03-17 Ajinomoto Company Incoporated Pharmaceutical composition having an excellent absorption property

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2102412A (en) * 1981-06-19 1983-02-02 Chugai Pharmaceutical Co Ltd Proline derivatives and process for producing the same
EP0093551A2 (en) * 1982-04-30 1983-11-09 Ajinomoto Co., Inc. Pharmaceutical composition
US4650785A (en) * 1982-04-30 1987-03-17 Ajinomoto Company Incoporated Pharmaceutical composition having an excellent absorption property
US4670584A (en) * 1982-04-30 1987-06-02 Ajinomoto Company Incorporated Pharmaceutical composition having an excellent absorption property

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
European Search Report/Application No. 86 30 2217/26 11 1987. *
European Search Report/Application No. 86 30 2217/26-11-1987.
Toyoshima et al., "Preparation of D-Phenylalanine Derivatives and Their Use as Hypoglycemic Agents", CA 106 85057d (1987).
Toyoshima et al., Preparation of D Phenylalanine Derivatives and Their Use as Hypoglycemic Agents , CA 106 85057d (1987). *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100076084A1 (en) * 1999-09-17 2010-03-25 Marjorie Regan Gatlin Method of Treating Metabolic Disorders, Especially Diabetes, or a Disease or Condition Associated with Diabetes
US20070275928A1 (en) * 1999-09-17 2007-11-29 Gatlin Marjorie R Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US20050124663A1 (en) * 1999-09-17 2005-06-09 Gatlin Marjorie R. Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US20050096367A1 (en) * 2002-05-28 2005-05-05 Yoshiro Kitahara Pharmaceutical composition for suppression of the expression of ATP citrate lyase and use thereof
US20090176835A1 (en) * 2002-05-28 2009-07-09 Ajinomoto Co., Inc. Pharmaceutical composition for suppression of the expression of atp citrate lyase and use thereof
US20040152782A1 (en) * 2002-07-03 2004-08-05 Ronit Yahalomi Process for preparing nateglinide and intermediates thereof
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US20050075400A1 (en) * 2002-07-18 2005-04-07 Ronit Yahalomi Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US20050014836A1 (en) * 2002-07-18 2005-01-20 Gustavo Frenkel Crystalline form of nateglinide
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US20070004804A1 (en) * 2002-07-18 2007-01-04 Teva Pharmaceuticals Usa, Inc. Polymorphic forms of nateglinide
US20050014949A1 (en) * 2002-07-18 2005-01-20 Ronit Yahalomi Polymorphic forms of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7420084B2 (en) 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US20080319075A1 (en) * 2002-07-18 2008-12-25 Ronit Yahalomi Polymorphic forms of nateglinide
US20050090552A1 (en) * 2002-07-18 2005-04-28 Ronit Yahalomi Polymorphic forms of nateglinide
US20040181089A1 (en) * 2002-07-18 2004-09-16 Ronit Yahalomi Polymorphic forms of nateglinide
US20040116526A1 (en) * 2002-07-18 2004-06-17 Ronit Yahalomi Polymorphic forms of nateglinide
US20100010240A1 (en) * 2006-01-26 2010-01-14 Iowa State University Research Foundation, Inc. Synthesis of polycyclic procyanidins
US7615649B2 (en) 2006-01-26 2009-11-10 Iowa State University Research Foundation, Inc, Synthesis of polycyclic procyanidins
US8138358B2 (en) 2006-01-26 2012-03-20 Iowa State University Research Foundation, Inc. Synthesis of polycyclic procyanidins
US8415489B2 (en) 2006-01-26 2013-04-09 Iowa State University Research Foundation, Inc. Synthesis of polycyclic procyanidins
WO2011157986A1 (en) 2010-06-14 2011-12-22 Cipla Limited A process for the preparation of nateglinide
US9150499B2 (en) 2010-06-14 2015-10-06 Cipla Limited Process for the preparation of nateglinide
US10006830B2 (en) 2015-05-20 2018-06-26 Nexion S.P.A. Balancing machine

Also Published As

Publication number Publication date
JPS6354321A (en) 1988-03-08
EP0196222A2 (en) 1986-10-01
EP0196222B1 (en) 1992-01-29
JPH0415221B2 (en) 1992-03-17
DE10199054I2 (en) 2006-04-27
DE10199054I1 (en) 2002-01-10
US4816484A (en) 1989-03-28
DE3683662D1 (en) 1992-03-12
EP0196222A3 (en) 1988-02-24

Similar Documents

Publication Publication Date Title
USRE34878E (en) Hypoglycemic agent
CA2036876C (en) Derivatives having a naphthalenic structure; process for preparing the same and pharmaceutical compositions containing them
KR950011120B1 (en) Lipoxygenase inhibiting compounds
US4661630A (en) Carboxylic acid amides and their derivatives
KR20080081099A (en) Substituted thiazolidinedione derivatives
US5240960A (en) 3-cycloalkyl-propanamides
US4134991A (en) Derivatives of 2-(3-phenyl-2-aminopropionyloxy)-acetic acid
US4880841A (en) Process of producing phenethylamine derivatives
HUT70488A (en) Condensed quinolyl-dihydropyridine derivatives, pharmaceutical compositions containing them and process for producing the compounds and the pharmaceutical compositions
AU2004235958B2 (en) Novel bioisosteres of actinonin
US4450172A (en) Antihypertensive polyhalohydroxyisopropyl phenylalka(e)noic acid esters of alkylaminohydroxypropyloxyphenylalkyl alcohols
US4728739A (en) Hypoglycemic thiazolidinediones
US4297357A (en) N-Phenethylacetamide compounds and process for preparation thereof
EP0146392A1 (en) B-phenethanolamine antiobesity agents
FR2460294A1 (en) NOVEL OXIME ETHERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
GB2053897A (en) Piperazine derivatives
US4775676A (en) Thiazolidine derivatives, process for their preparation and pharmaceutical compositions
US3856951A (en) Substituted benzoic acid hypoliphemic agents
US3979402A (en) Thiazole derivatives
US4269855A (en) (3-Alkylamino-2-hydroxypropoxy)-furan-2-carboxylic acid anilides and physiologically tolerated acid addition salts thereof and medicaments containing them
US4713390A (en) Sulfurated hydantoin derivatives and pharmaceutical compositions containing same
US4774259A (en) Phenylalanine derivatives and uses thereof
US4051251A (en) Novel anti-hypertensive compositions
BE897146A (en) APOVINCAMINIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE DERIVATIVES
FR2531704A1 (en) N-SUBSTITUTED AROMATIC ACID (HETERO) AMALIDES, THEIR SALTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12

PTEF Application for a patent term extension

Free format text: PRODUCT NAME: STARLIX (NATEGLIDE); REQUESTED FOR 1259 DAYS

Filing date: 20010214

Expiry date: 20080121

PTEG Grant of a patent term extension

Free format text: PRODUCT NAME: STARLIX (NATEGLIDE)

Filing date: 20010214

Expiry date: 20080121